A rapid and versatile tool for genomic engineering in Lactococcus lactis

Abstract

BackgroundLactococcus lactis is one of the most extensively characterized lactic acid bacteria, from physiological traits to industrial exploitation. Since last decade, L. lactis has been developed into cell factories for the production of bioactive compounds such as enzymes, vaccine antigens and natural products. However, its precise and efficient genome editing tools is still required to make L. lactis more suitable candidate for engineered functionality.ResultsA high active recombinase, RecT of Enterococcus faecalis ATCC14506, was selected from six candidates and mediated homologous recombination between single-stranded DNA (ssDNA) and the L. lactis chromosomal rpoB locus with an efficiency of 100% after rifampin selection. To screen mutants without an externally selectable phenotype, the CRISPR/Cas9 system was used for counterselection, yielding an upp mutant with an efficiency of 46%. By optimization of the copy number of plasmid carrying the CRISPR/Cas9 system and the length of spacer sequence, the off-target efficiency of the recA, galK, hemN and noxD genes were eliminated. The ability of this optimized tool to perform sequential point mutation was demonstrated using the upp and galK gene loci as targets with improved efficiencies > 75%. Moreover, seamless genomic DNA deletions (50/100 bp) or insertion (a loxP site, 34 bp) was efficiently accomplished within 72 h.ConclusionsThe work provided a rapid, versatile and precise tool for L. lactis genomic engineering by combination of ssDNA recombineering with improved CRISPR/Cas9 counterselection. This tool will simplify the production of isogenic strains for assessment of gene function or construction of biosynthetic host.Electronic supplementary materialThe online version of this article (10.1186/s12934-019-1075-3) contains supplementary material, which is available to authorized users.

Engineering Lactococcus lactis for Increased Vitamin K2 Production

“…The use of geneticallymodified organisms (GMOs) for food production is under heavy jurisdiction in most countries, nevertheless over 100 GMOs are approved worldwide for use in commercial food or feed so far (Kamle et al, 2017). The rise of CRISPR-technology, to make precise genetic alterations in organisms ranging from bacteria like L. lactis (Guo et al, 2019) to human beings, is also believed to impact the legislation around GMO's and food production possibly enabling the use of such GMO's in a near future.…”

Developing a new class of engineered live bacterial therapeutics to treat human diseases

“…Probiotics in the genera Lactobacillus and Lactococcus have also attracted significant attention in the engineered biotherapeutic arena. Though the genetic toolbox for these organisms is less advanced than that of E. coli, progress has been made with regard to genetic modification and control of gene expression in these organisms 39,40 . Similar to EcN, these genera do not colonize the human gut, thus allowing for predictive pharmacokinetic profiling of therapeutic strains 41,42 .…”

Safety Aspects of Genetically Modified Lactic Acid Bacteria

“…Recombineering has been demonstrated to be an effective tool in the incorporation of chromosomal mutations in Lactobacillus reuteri and L. lactis [40]. Moreover, the efficiency of recombineering in genomic engineering of L. lactis [41] and L. reuteri was improved by the use of CRISPR-Cas9 [42], which is addressed below in more detail.…”